Mirum Pharmaceuticals (MIRM) Gross Profit (2021 - 2026)

Mirum Pharmaceuticals' Gross Profit history runs 6 years deep, the most recent figure standing at $131.1 million for Q1 2026.

• On a quarterly basis, Gross Profit rose 48.0% year-over-year to $131.1 million in Q1 2026; TTM through Mar 2026 was $463.6 million, a 58.53% increase from a year earlier, with the FY2025 full-year figure at $421.1 million, up 64.97% from the prior year.
• Gross Profit rose to $131.1 million in Q1 2026 per MIRM's latest filing, from $120.7 million in the prior quarter.
• Across five years, Gross Profit topped out at $131.1 million in Q1 2026 and bottomed at $10.5 million in Q1 2022.
• The 5-year median for Gross Profit is $51.4 million (2024), against an average of $59.5 million.
• Biggest YoY gain for Gross Profit was 1795.71% in 2022; the steepest drop was 36.0% in 2022.
• Year by year, Gross Profit stood at $23.4 million in 2022, then surged by 90.22% to $44.5 million in 2023, then jumped by 72.08% to $76.6 million in 2024, then surged by 57.46% to $120.7 million in 2025, then rose by 8.63% to $131.1 million in 2026.
• Per Business Quant, the three latest MIRM Gross Profit figures stand at $131.1 million (Q1 2026), $120.7 million (Q4 2025), and $107.5 million (Q3 2025).